Why partner with us

We have a track record of successful scientific and development collaborations that demonstrate efficiency, innovation, and strong relationships with our service partners. We are collaborating with partners to advance our drug development programs and are keenly interested in developing and integrating novel differentiated programs and platforms.

Michael Schaeffer, PhD
Chief Business Officer

What drives us

We want to bring pharmaceutical innovation to the patients in need.


patients worldwide suffer from AD


is the timespan in which someone in the US is diagnosed with AD


AD patients currently live in the EU


patients worldwide are diagnosed with cancer every year

What We’re Focused On

We are focused on building a differentiated portfolio of transformational medications with a single goal in mind: improving the lives of all those who are affected by severe diseases.

Alzheimer's Disease

  • Small molecules with good blood-brain barrier penetration
  • Inhibiting the occurrence of especially synaptotoxic glutaminylated soluble Abeta peptides
  • One of the most advanced AD trials globally
  • Clear clinical development path forward

Cancer Checkpoint Inhibition

  • Small molecules to modulate cancer immune checkpoint activity
  • Precision intervention to augment innate immune system activity
  • Combination therapeutics


  • Small molecule modulators of Glutaminyl cyclase enzymes
  • Large portfolio of inhibitors with long patent runtimes
  • Small molecules as co-medication therapies with anti-tumor antibodies
  • Differentiated efficacy profiles for the application inside or outside the brain


  • Modulating the activity of post-translational modifying enzymes
  • Rapid development potential from concept to clinial phase
  • Biomarker based clinical research
  • Working with the best experts and technology providers in their field